The Effect of Infliximab Therapy in Crohn Patients on Regulatory T-cells
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- Change from baseline in number of regulatory T-cells at 6 weeks
研究概览
简要总结
Aim: the main aim of this study is to investigate if immune cells (regulatory T-cells, Th17 cells and other immune cell types) or biomarkers can be used to predict the response or lack of response to treatment with Infliximab. If so, characteristics of the immune cells may also unveil the mechanisms behind lack of response to Infliximab.
Design: a prospective, observational study with three arms. In the treatment group, 35 patients with Crohn's disease about to start Infliximab-treatment are recruited. They have blood samples drawn at day 1 before first treatment, after 6 week, and again after 22 weeks of treatment. 12 healthy volunteers serve as a control group. Controls are only investigated once. All treatment and follow-up are according to national guidelines, and data from this study is not used by the clinicians.
Methods: the number of regulatory T-cells and pro-inflammatory T-cells (Th17 cells) is investigated using flow cytometry. From plasma and serum samples, various proteins (biomarkers), such as transforming growth factor beta (TGF-beta) and tumour necrosis factor alpha (TNF-alpha), are measured using immunoassays. Patient data (demographics and medical history) are extracted from various registries.
详细描述
Primary analyses: patient response to Infliximab treatment is quantified using Harvey Bradshaw Index, and the response is then related to the number of regulatory T-cells, Th17 cells, and biomarker levels at baseline. The exact cut-off for response vs. non-respons will be determined and validated once all data is collected by an assessor blinded for the flow cytometry results and biomarker levels.
Plan for missing data: for patients with missing Harvey Bradshaw Index, we will first try to re-create the score using the patient records (information on well-being, abdominal pain, diarrhea, fistulae/abscesses, and extra-intestinal Crohn manifestations). If this is not possible, an experienced clinician will rate the patient's Infliximab response based on all available patient record data, but blinded for flow cytometry results and biomarker levels.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Crohn's Disease
- •Starting Infliximab treatment
- •Patient at the gastrointestinal department at Hvidovre Hospital or Køge Sygehus
- •Can understand and write Danish
- •European ancestry
排除标准
- •Not able to consent in an ethical manner (e.g. severe mental illness)
- •Significant co-morbidity (e.g. cancer, HIV)
- •Other immunological disease (e.g. psoriasis)
- •Current treatment with biological agents
- •Healthy controls
- •Inclusion Criteria:
- •No current disease
- •No daily drug use
- •Can understand and write Danish
- •European ancestry
- •Exclusion Criteria:
- •Not able to consent in an ethical manner (e.g. severe mental illness)
- •Significant co-morbidity (e.g. cancer, HIV)
- •Other immunological disease (e.g. psoriasis)
- •Current treatment with biological agents
研究组 & 干预措施
Infliximab
35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
干预措施: Infliximab (Drug)
结局指标
主要结局
Change from baseline in number of regulatory T-cells at 6 weeks
时间窗: Baseline, 6 weeks (plus/minus 1 week)
The number of regulatory T-cells is measured in fresh blood by flow cytometry.
Change from baseline in number of regulatory T-cells at 22 weeks
时间窗: Baseline, 22 weeks (plus/minus 1 week)
The number of regulatory T-cells is measured in fresh blood by flow cytometry.
次要结局
- Change from baseline in Harvey Bradshaw Index at 6 weeks(Baseline, 6 weeks (plus/minus 1 week))
- Change from baseline in CD161 expression at 6 weeks(Baseline, 6 weeks (plus/minus 1 week))
- Change from baseline in CD161 expression at 22 weeks(Baseline, 22 weeks (plus/minus 1 week))
- Change from baseline in cytokine levels at 22 weeks(Baseline, 22 weeks (plus/minus 1 week))
- Change from baseline in Harvey Bradshaw Index at 22 weeks(Baseline, 22 weeks (plus/minus 1 week))
- Change from baseline in cytokine levels at 6 weeks(Baseline, 6 weeks (plus/minus 1 week))
研究者
Ove Andersen
MD, PhD
Hvidovre University Hospital